The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression

Immune-checkpoint inhibitors (ICIs) have become the mainstay of treatment for many malignancies. With this new strategy, relevant immune-related adverse events (irAEs) have been reported, some of which can be mistaken for disease progression. To better illustrate the current challenges in diagnosing...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantarotto, Marcos, Barata, Rita, Coelho, Ricardo, Sousa, Virginia, Carvalheiro, Catarina, Rolim, Ines, Garrido, Patricia, GIl, Nuno, Duarte-Ramos, Filipa, Tonin, Fernanda S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364060/
https://www.ncbi.nlm.nih.gov/pubmed/35967142
http://dx.doi.org/10.7759/cureus.26729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364060/
https://www.ncbi.nlm.nih.gov/pubmed/35967142
http://dx.doi.org/10.7759/cureus.26729

Ejemplares similares